Türkiye has become one of the busiest medical tourism destinations in the world, and that rise has provoked a backlash across Europe. Hurriyet Daily News reported that promotional campaigns in the United Kingdom, France and Germany have sought to frame Turkish healthcare as cheap but risky, a message that industry figures inside Türkiye say has dented patient travel and hardened opinion in exactly the markets that send the most patients. Turkish medical tourism operators have answered with campaigns of their own, emphasising safety, clinical standards and the quality of care available in the country’s hospitals and clinics.
Türkiye Medical Tourism Growth and 2025 Figures
Official data set out the scale of the sector. Hurriyet Daily News reported that 1.39 million foreign patients travelled to Türkiye for treatment in 2025, generating $3.02 billion in revenue. That was a small decline from 2024, when 1.5 million patients produced more than $3 billion, a fall of about 7 per cent in patient volume that sector leaders attribute to the perception campaigns running in Europe. The industry has not retreated. Turkish medical tourism operators have set ambitious targets for 2026 of 2.5 million health tourists and $10 billion in revenue.
Europe remains Türkiye’s primary source market, followed by the United States, the Middle East and the Gulf countries. Demand concentrates in a familiar set of procedures - hair transplantation, medical aesthetics, plastic surgery and general surgery - the elective, high-value work that has defined the country’s reputation. The economics explain the strategy. Hurriyet Daily News reported that an ordinary tourist spends about $800 during a stay in Türkiye, while the average health tourist spends between $3,000 and $4,000. A medical tourist is worth several holidaymakers, which is why the segment carries weight out of proportion to its headcount.
That contrast maps onto the five drivers of medical travel that shape every destination market, because patients cross borders for care that is better, best, cheaper, faster, or simply unavailable at home. Türkiye’s pitch rests mainly on the cheaper and faster axes, and the rival campaigns are engineered to attack the one variable a price-led destination cannot easily defend, which is trust. Price is easy to copy. Trust is not.
European Rival Campaigns Target Turkish Clinics
Industry figures told Hurriyet Daily News that negative advertising has intensified in the United Kingdom, Germany and France. Some messages are blunt, warning would-be patients not to have a hair transplant in Türkiye because they could die, while others allege that clinics are inspected too rarely. From the view of Turkish operators, the timing and the wording of the messaging point to a deliberate effort to divert patient flows rather than to inform. Hurriyet Daily News reported patient losses in the range of 15 to 30 per cent, focused on first-time medical tourists and people weighing Türkiye for the first time.
The pattern illustrates one of the four risks that shadow all medical travel, which are clinical risk, legal and redress risk, continuity-of-care risk, and geopolitical or logistical exposure. Hostile campaigns weaponise the first of these, because clinical anxiety is easiest to inflame in a patient who has never crossed a border for surgery and has no personal reference point. The hair transplant segment is especially exposed, sitting across the medical and cosmetic line, where facilitators and agencies often compete on visibility rather than on verifiable outcomes.
How Turkish Operators Are Responding
Turkish medical tourism operators have not absorbed the losses. They have pushed back on several fronts. Hurriyet Daily News reported that they have begun legal action against content judged misleading or defamatory, run social media campaigns showcasing their hospitals and clinical quality, and expanded promotion in key overseas markets. The most concrete step is opening pre-diagnosis centres in several countries, giving would-be patients an in-country point of contact before they commit to travelling.
The pre-diagnosis model is the more durable of these moves. A defamation suit contests a single message, but an accredited assessment on the patient’s doorstep changes the first experience of the destination, which is where first-time medical tourists form their judgement. Internationally accredited clinics with a documented referral history hold the strongest hand here, and the operators best served by the campaign are those who can point to outcomes rather than adjectives.
TÜRSAB on Speed, Cost and Patient Flow
Şehnaz Atak Askeroğlu, who chairs the Health Tourism Specialisation Department at TÜRSAB, the Association of Turkish Travel Agencies, rejected the picture painted by the negative reports. She said Türkiye still draws heavy demand, arguing that “Türkiye receives a very serious patient flow” that rivals cannot easily replicate on speed or cost. She pointed to waiting times as the decisive factor, noting that even a simple treatment in the United Kingdom can require a wait of three to four months, whereas Turkish clinics deliver high-standard care quickly and at lower cost. Askeroğlu added that accredited clinics with strong references tend to suffer least from the campaigns.
What the Perception Battle Means for Medical Tourism
The structural weakness the episode exposes is concentration. Europe is at once Türkiye’s largest source market and the region running the campaigns, which means the demand base and the threat to its name sit in the same place. A destination that leans on one region for the bulk of its patients inherits that region’s own politics, and spreading towards the United States, the Middle East and the Gulf is as much a hedge as a growth plan.
The defensible response is unglamorous. Speed and price brought the patients, but the campaigns target trust, and trust is rebuilt through published outcomes, transparent inspection regimes and the accreditation that operators keep citing. Hurriyet Daily News reported 1.39 million patients in a year when rivals were spending to talk them out of the trip, which suggests the underlying demand is real. Converting that demand into a durable position depends less on winning the advertising exchange than on fixing the quieter machinery of quality assurance that a price-led destination is always tempted to skip.
